Trial Profile
An open-label, phase III study to evaluate the efficacy and safety of MRA [tocilizumab] in patients with RA [rheumatoid arthritis]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary) ; Disease-modifying antirheumatics
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Acronyms SAMURAI
- Sponsors Chugai Pharmaceutical